

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.elsevier.com/locate/ajur



An unusual scrotal mass: Morphological clues



()

ASIAN JOURNAL OF UROLOGY

60x 301+ 3662 phon 0+ 31-01347 60x 2014 3660 phone

Poojan Agarwal*, Anila Sharma, Sunil Pasricha, Anurag Mehta

Department of Laboratory Services, Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, India

Received 3 September 2018; received in revised form 28 June 2019; accepted 27 September 2019; Available online 10 December 2019

A 21-year-old male presented with complaints of swelling and dragging sensation in the scrotum for 6 months. Local examination revealed a firm 10 cm \times 6 cm \times 4 cm lump with nonpalpable right testis. Overlying skin was free. Ultrasonography showed a mass lesion in the right testicular area with multiple heterogeneous foci and mild increased vascularity, however, without any cystic region and calcification. Right epididymis was also bulky and measured 1.6 cm \times 0.7 cm with heterogeneous texture. No significant inguinal lymphadenopathy was present. Features were suggestive of a neoplastic lesion. Patient's serum lactate dehydrogenase (LDH), alpha feto-protein (AFP), beta-Human chorionic gonadotropin (β -HCG), complete blood count, liver and kidney function tests were within normal limits. A high inguinal orchidectomy was subsequently done. Gross examination revealed a firm oval mass with glistening external surface. Cut surface showed residual normal testis as a discrete nodule in center measuring 2.8 cm×2.5 cm×0.8 cm, encased by a large firm white lesion. Layers of tunica were embedded within the tumor. Microscopy revealed a pleomorphic tumor comprising of small undifferentiated cells having hyperchromatic nuclei and intermixed spindle cells. Many bizarre nuclei with evident multinucleation were also seen. Few cells with tadpole and strap cell like morphology were noted

interspersed. A typical mitosis and foci of necrosis were present. Based on histomorphology, the differentials considered were rhabdomyosarcoma, undifferentiated sarcoma, sex cord stromal tumor and anaplastic seminoma. A panel of immunohistochemistry was put up to differentiate amongst these lesions (Table 1). On immunohistochemistry, the tumor cells expressed desmin, myogenin (diffuse) and myoD1 (weak and focal) while they were negative for cytokeratin (CK), sallike protein 4 (SALL4), placental alkaline phosphatase (PLAP), s-100, Steroidogenic factor-1 (SF-1) and inhibin (Fig. 1 and Fig. 2). A final diagnosis of embryonal rhabdomyosarcoma--Anaplastic variant was made (pT2N0 stage 1B). A combination chemotherapy was given with vincristine, actinomycin and cyclophosphamide (VAC) alternating with ifosfamide and etoposide (IE) regimen every three weekly. Radiation consisted of external beam therapy. The patient was doing well on 3 month follow-up.

The paratesticular region is a complex anatomical area which includes the contents of the spermatic cord, testicular tunics, epididymis and vestigial remnants of epithelial, mesothelial or mesenchymal origin. Tumors affecting this region may be clinically indistinguishable from testicular tumors, thus resulting in initial misdiagnosis. On rare occasions, tumors from distant sites may metastasize to the

E-mail address: poojanagarwal@gmail.com (P. Agarwal). Peer review under responsibility of Second Military Medical

University.

https://doi.org/10.1016/j.ajur.2019.12.005

^{*} Corresponding author.

^{2214-3882/© 2021} Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Table 1 Morphological differencials and chen differenciating inc prome.				
Morphological differentials/IHC	Rhabdomyosarcoma	Undifferentiated sarcoma	Sex cord stromal tumor	Seminoma
СК	_	_	+/-	_
Vimentin	+	+	-	+
s-100	-	-	-	_
CD34	-	+	-	_
Myogenin	+	-	-	-
Desmin	+	-	-	_
SALL-4	-	-	-	+
PLAP	-	-	Not known	+
SF-1	-	-	+	-
Inhibin	-	-	+	-

IHC, immunohistochemistry; CK, cytokeratin; SALL-4, sal-like protein 4; PLAP, placental alkaline phosphatase; SF-1, steroidogenic factor 1. + refers to positive; - refers to negative, +/- refers to variable expression.



Morphological differentials and their differentiating IHC profile

Figure 1 Gross picture of the testicular tumor.



Figure 2 Micro-photographs of the testicular tumor. (A) Tumor tissue abutting seminiferous tubules $(100\times; H\&E)$; (B) Multinucleate tumor cells with abundant eosinophilic cytoplasm and peripherally pushed nuclei suggestive of rhabdoid differentiation $(400\times; H\&E)$; (C) Scattered tadpole shaped cell seen in the center of field $(400\times; H\&E)$; (D) Bizarre tumor cells with scattered mitotic figure $(400\times; H\&E)$; (E) Immunohistochemical stain for desmin $(400\times)$; (F) Immunohistochemical stain for myogenin $(400\times)$.

paratesticular region [1]. These lesions typically present as a rapidly growing and painless intrascrotal mass, eliciting only anatomically associated symptoms.

Seventy percent of paratesticular tumors reported are benign and 30% are malignant. The common benign tumors reported in paratestis include lipomas, adenomatoid tumors and leiomyomas. Among the malignant tumors, the most common histological type reported is liposarcoma (46.4%), followed by leiomyosarcoma (LMS) (20%), malignant fibrous histiocytomas (MFH) (13.0%), and embryonal rhabdomyosarcoma (9.0%) [2].

Para testicular rhabdomyosarcoma (RMS) is a rare entity, accounting for 7% of all RMS reported and is uncommon in adults [3]. Eighty percent of the lesions occur in individuals <21 years of age [4]. Embryonal RMS (ERMS) is the most common subtype reported. ERMS further has botryoid and anaplastic variants. The anaplastic variant is a distinctive RMS subtype. The presence of markedly enlarged, atypical cells with hyperchromatic nuclei defines the anaplastic variant of rhabdomyosarcoma. Previously these tumors were stratified under alveolar or embryonal RMS, however, because of their poorer clinical outcome and lack of PAX-FOXO1 fusion gene. several authors now consider that these cases should be grouped separately as anaplastic RMS [5]. Few studies have also found germline TP53 mutations in individuals diagnosed with anaplastic RMS at a young age. Early identification of germline mutation paves path for subsequent surveillance and early diagnosis of second malignancies [6].

We discuss a case of ERMS with anaplastic features as it is a rare entity and definitive management protocols are lacking. In the absence of protocols designed specifically for adult patients, it is imperative to follow pediatric therapeutic guidelines. Anaplastic RMS of the paratestis should be considered in differential diagnosis when dealing with scrotal masses of high grade histomorphology, for a better and aggressive patient management.

Author contributions

Study design: Poojan Agarwal, Anila Sharma. Data acquisition: Anila Sharma, Anurag Mehta. Data analysis: Anila Sharma, Sunil Pasricha, Poojan Agarwal. *Drafting of manuscript*: Poojan Agarwal, Anila Sharma, Sunil Pasricha.

Critical revision of the manuscript: Poojan Agarwal.

Conflicts of interest

The authors declare no conflict of interest.

References

 Aydin GB, Ciftçi AO, Yalçin B, Akçören Z, Cağlar M, Senocak ME, et al. Paratesticular metastasis from Wilms tumor associated with a hydrocele. Pediatr Blood Cancer 2006;47:97–9.

- [2] Khoubehi B, Mishra V, Motiwala H, Karim O. Adult paratesticulartumors. BJU Int 2002;90:707–15.
- [3] Kumar R, Kapoor R, Khosla D, Kumar N, Ghoshal S, Mandal AK, et al. Paratesticular rhabdomyosarcoma in young adults: a tertiary care institute experience. Indian J Urol 2013;29:110–3.
- [4] Huddart RA, Patrikidou A. Paratesticular tumors. In: Pagliaro L, editor. Rare genitourinary tumors. 1st ed. Switzerland: Springer; 2016. p. 261–80.
- [5] Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. WHO classification of tumors of soft tissue and bone. Lyon: WHO Press; 2013. p. 127.
- [6] Hettmer S, Archer NM, Somers GR, Novokmet A, Wagers AJ, Diller L, et al. Anaplastic rhabdomyosarcoma in *TP53* germline mutation carriers. Cancer 2014;120: 1068–75.